Literature DB >> 11713443

Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial.

F Gottrand1, N Kalach, C Spyckerelle, D Guimber, J F Mougenot, P Tounian, C Lenaerts, B Roquelaure, A Lachaux, A Morali, C Dupont, C Maurage, M O Husson, P Barthélemy.   

Abstract

OBJECTIVES: The aim of this multicenter prospective, randomized, double-blind study was to assess the efficacy of the combination of omeprazole, amoxicillin, and clarithromycin (OAC) for the treatment of Helicobacter pylori gastritis in children. STUDY
DESIGN: Seventy-three children with dyspeptic symptoms were included in the trial (mean age 10.8 years; range, 3.3 to 15.4). Patients were randomized to receive OAC or amoxicillin and clarithromycin (AC) for 7 days. H pylori status was assessed before and 4 weeks after eradication treatment, by use of the carbon 13-labeled urea breath test.
RESULTS: In intent-to-treat analysis (n = 63), eradication rates were 74.2% (95% CI, 58.7 to 89.6) in the OAC group and 9.4% (95% CI, 0 to 19.5) in the AC group. In per-protocol analysis (n = 53), the eradication rate increased to 80% (95% CI, 64.3 to 95.7), remaining significantly higher than in AC group (10.7%; 95% CI, 0 to 22.2). Resistance of strains to clarithromycin was rare (3/39 = 7.7%) and was not associated with failure of treatment. Adverse events were reported in 24.6% of patients and remained mild.
CONCLUSION: This study shows that 1-week OAC triple therapy results in successful eradication of H pylori in 75% of children with gastritis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713443     DOI: 10.1067/mpd.2001.118197

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  A review of current guidelines for the management of Helicobacter pylori infection in children and adolescents.

Authors:  Nicola L Jones
Journal:  Paediatr Child Health       Date:  2004-12       Impact factor: 2.253

2.  Safety and tolerability of clarithromycin administered to children at higher-than-recommended doses.

Authors:  D A Kafetzis; F Chantzi; G Tigani; C L Skevaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-02       Impact factor: 3.267

3.  Furazolidone-based triple therapy for H pylori gastritis in children.

Authors:  Elisabete Kawakami; Rodrigo Strehl Machado; Silvio Kazuo Ogata; Marini Langner; Erika Fukushima; Anna Paula Carelli; Vania Cláudia Guimarães Bonucci; Francy Reis Silva Patricio
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

Review 4.  Pharmacokinetics of proton pump inhibitors in children.

Authors:  Catherine Litalien; Yves Théorêt; Christophe Faure
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children.

Authors:  Shan Li; Xiu-li Huang; Jing-zhe Sui; Si-yuan Chen; Yan-tong Xie; Yan Deng; Jian Wang; Li Xie; Tai-jie Li; Yu He; Qi-liu Peng; Xue Qin; Zhi-yu Zeng
Journal:  Eur J Pediatr       Date:  2013-12-10       Impact factor: 3.183

6.  Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.

Authors:  Chika Kusano; Takuji Gotoda; Sho Suzuki; Hisatomo Ikehara; Mitsuhiko Moriyama
Journal:  J Gastroenterol       Date:  2017-11-07       Impact factor: 7.527

Review 7.  The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis.

Authors:  Angelo Zullo; Vincenzo De Francesco; Cesare Hassan; Sergio Morini; Dino Vaira
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

Review 8.  The use of proton pump inhibitors in children: a comprehensive review.

Authors:  Troy E Gibbons; Benjamin D Gold
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 9.  Advances in the treatment of Helicobacter pylori infection in children.

Authors:  Nicolas Kalach; Patrick Bontems; Samy Cadranel
Journal:  Ann Gastroenterol       Date:  2015 Jan-Mar
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.